Gynecological Cancers Therapeutics Market Size to Reach USD 37.57 Billion by 2035, Driven by Precision Oncology Trends

Overview

According to DataM Intelligence, the global gynecological cancers therapeutics market was valued at USD 18.40 billion in 2025 and is forecast to reach USD 37.57 billion by 2035, expanding at a CAGR of 7.4% during 2026–2035.

The market is increasingly shaped by precision treatment approaches that connect cancer biology with therapy selection. Ovarian cancer treatment includes PARP maintenance, FRα-directed ADC therapy, KRAS-selected treatment and PD-L1-selected immunotherapy, while endometrial cancer treatment increasingly incorporates molecular characteristics such as MMR and MSI status. Cervical cancer has also moved toward broader immunotherapy use, including pembrolizumab alongside definitive chemoradiotherapy. These developments are strengthening demand for targeted therapies, antibody-drug conjugates, immunotherapy and biomarker-based treatment pathways.

Get More Insights from the Full Research Report: https://www.datamintelligence.com/research-report/gynecological-cancers-therapeutics-market?indhu

Recent Developments

• Merck — 2026: Merck reported positive Phase III results for pembrolizumab monotherapy in first-line dMMR advanced or recurrent endometrial cancer, with the treatment significantly improving progression-free survival compared with platinum chemotherapy.

• Merck — 2026: The company announced positive Phase III TroFuse-005 results for sacituzumab tirumotecan in advanced or recurrent endometrial cancer following platinum chemotherapy and prior immunotherapy, meeting both overall-survival and progression-free-survival endpoints.

• GSK — 2026: GSK reported early BEHOLD-1 results for mocertatug rezetecan, a B7-H4-directed ADC, and outlined five Phase III programs across ovarian and endometrial cancer.

• AbbVie — 2026: AbbVie reported clinical results for Elahere plus carboplatin followed by Elahere continuation therapy in FRα-expressing platinum-sensitive recurrent ovarian cancer.

• Corcept Therapeutics — 2026: FDA approved Lifyorli/relacorilant plus nab-paclitaxel for previously treated platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after prior bevacizumab.

• Merck — 2026: FDA approved pembrolizumab with paclitaxel, with or without bevacizumab, for previously treated PD-L1-positive platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.

Mergers & Acquisitions

• Gilead Sciences & Tubulis – May 2026: Gilead Sciences completed the acquisition of Tubulis, adding its next-generation antibody-drug conjugate platform and TUB-040, an investigational ADC being developed for platinum-resistant ovarian cancer, strengthening Gilead’s oncology portfolio in gynecological cancers. 

• Novartis & Myricx Bio – July 2026: Novartis agreed to acquire Myricx Bio, adding its antibody-drug conjugate assets and N-myristoyltransferase inhibitor platform, with potential applications across solid tumors and strengthening Novartis’ oncology pipeline. 

• Gedeon Richter & Celmatix – March 2026: Gedeon Richter acquired Celmatix’s women’s health discovery portfolio, adding early-stage therapeutic programs and strengthening its drug-development capabilities across women’s health, including ovarian-related indications.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for Quick Response): https://www.datamintelligence.com/download-sample/gynecological-cancers-therapeutics-market?indhu

Gynecological Cancers Therapeutics Market Segmentation

By Cancer Type

• Uterine Cancer

• Ovarian Cancer

• Vaginal & Vulvar Cancer

• Cervical Cancer

Cancer type segmentation reflects the different therapeutic requirements across gynecological malignancies. The report separately emphasizes ovarian/fallopian/primary peritoneal, endometrial/uterine, cervical, vulvar/vaginal and uterine sarcoma categories in its broader market analysis.

By Therapy

• Targeted Therapy

• Avastin

• Lynparza

• Zejula

• Rubraca

• Vitrakvi

• Tivdak

• Votrient

• Chemotherapy

• Dacarbazine (DTIC)

• Gemcitabine (Gemzar)

• Epirubicin (Ellence)

• Paclitaxel (Taxol)

• Platinol

• Paraplatin

• Immunotherapy

• Keytruda

• Hormonal Therapy

• Goserelin (Zoladex)

• Leuprolide (Lupron)

• Megestrol (Megace)

• Tamoxifen

• Anastrozole (Arimidex)

Therapy segmentation captures established chemotherapy and hormonal treatments alongside targeted medicines, immunotherapy and ADC-based approaches. The report identifies targeted therapy and ADCs as the largest therapy segment, while immunotherapy is gaining importance across endometrial, cervical and selected ovarian cancers.

By End-user

• Hospitals

• Cancer Centers

• Clinics

• Ambulatory Surgical Centers

• Others

End-user segmentation reflects the healthcare settings through which gynecological cancer therapies are delivered. Hospitals and cancer centers remain important treatment environments as therapies become more specialized and increasingly dependent on biomarker-based selection.

By Region

• North America

• Latin America

• Europe

• Asia Pacific

• Middle East

• Africa

Regional segmentation captures differences in market size and treatment adoption across major geographic markets. North America leads the global market, while Asia-Pacific is identified as the fastest-growing region.

Competitive Landscape

The gynecological cancers therapeutics market is characterized by competition across immunotherapy, targeted therapies, PARP inhibitors, chemotherapy, hormonal treatments, and antibody-drug conjugates. The competitive environment is increasingly influenced by the development of biomarker-selected therapies and treatments designed for specific cancer types or disease stages. Companies are advancing therapies targeting biomarkers such as MMR/MSI, PD-L1, FRα, BRCA/HRD, and KRAS, while ADC development is expanding across ovarian and endometrial cancers. 

Top key players

• Merck & Co.

• GSK

• AstraZeneca

• AbbVie

• Pfizer / Genmab

Company Profiles

Merck & Co.: Merck has a broad gynecological oncology position through pembrolizumab across endometrial and cervical cancer and its newer ovarian indication. The company is also advancing sacituzumab tirumotecan in endometrial cancer.

GSK: GSK's women's cancer portfolio includes Jemperli/dostarlimab and Zejula/niraparib, alongside development of mocertatug rezetecan, a B7-H4-directed ADC.

AbbVie: AbbVie has established a major ovarian cancer position through Elahere, with the report highlighting continued development of the FRα-directed ADC in earlier treatment settings.

Speak to Our Analyst and Get Customization in the Report as per Your Requirements: https://www.datamintelligence.com/customize/gynecological-cancers-therapeutics-market?indhu

Regional Analysis

Europe

Europe accounted for 26.7% of global revenue in 2025, according to the DataM Intelligence report, making it the second-largest regional market after North America. Germany represented 5.2% of global revenue, followed by the UK at 4.4%, France at 4.0%, Italy at 2.7% and Spain at 2.4%.

The region's market is increasingly influenced by biomarker-defined therapies and advanced treatment options, including checkpoint inhibitors, PARP inhibitors and antibody-drug conjugates. The report identifies North America as the dominant region with a 42.4% share, while Asia-Pacific is the fastest-growing region. Europe therefore occupies an important middle position between the established North American market and the faster-growing Asia-Pacific market.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=gynecological-cancers-therapeutics-market?indhu

Conclusion

The gynecological cancer therapeutics market share is moving toward more differentiated treatment pathways built around cancer type, molecular characteristics and therapeutic mechanism. Ovarian cancer remains the largest cancer segment, while targeted therapies and ADCs represent the leading therapy category. Immunotherapy is also gaining ground as treatment expands across endometrial and cervical cancers and into biomarker-selected ovarian cancer.

The competitive environment is centered on companies developing checkpoint inhibitors, PARP therapies, ADCs and molecularly selected treatments. Regional performance remains led by North America, with Europe representing a substantial share and Asia-Pacific showing the fastest growth. Overall, the market direction described by DataM Intelligence points toward increasingly biomarker-driven treatment selection and continued development of targeted and immune-based therapies through 2035.